NGNE
Neurogene Inc. NASDAQ Listed Mar 7, 2014$35.31
-0.82%
vs $35.60
Mkt Cap $558.0M
52w Low $15.93
69.9% of range
52w High $43.66
50d MA $32.30
200d MA $25.26
P/E (TTM)
—
EV/EBITDA
—
P/B
2.8x
Debt/Equity
0.0x
ROE
-34.1%
P/FCF
-9.6x
RSI (14)
40.40
ATR (14)
$1.84
Beta
1.89
50d MA
$32.30
200d MA
$25.26
Avg Volume
269.8K
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
535 W 24th Street · New York City, NY 10011 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | AMC | -1.30 | -1.39 | -7.2% | 31.54 | +0.0% | +3.4% | -4.1% | -4.6% | -6.2% | -3.9% | — |
| May 8, 2026 | BMO | — | — | — | 31.26 | -2.5% | -1.5% | +0.4% | +2.1% | +3.4% | -4.1% | — |
| May 7, 2026 | BMO | — | — | — | 32.33 | -0.1% | -3.3% | -1.5% | +0.4% | +2.1% | +3.4% | — |
| Mar 24, 2026 | AMC | -1.24 | -1.12 | +9.6% | 20.90 | +1.6% | +5.4% | -2.8% | -5.0% | -5.2% | +4.5% | — |
| Nov 13, 2025 | AMC | -1.26 | -0.99 | +21.4% | 26.49 | +1.7% | -14.0% | -1.4% | -4.9% | -1.7% | -2.8% | — |
| Aug 11, 2025 | AMC | -1.15 | -1.05 | +8.7% | 20.35 | -1.9% | -5.6% | +9.8% | -4.3% | +1.5% | -0.3% | — |
| May 9, 2025 | AMC | -1.05 | -1.08 | -2.9% | 14.73 | +5.1% | +20.2% | -12.4% | -1.9% | +27.3% | -7.1% | — |
| Mar 24, 2025 | AMC | -1.04 | -0.99 | +4.8% | 13.96 | +1.5% | +1.7% | +13.7% | -5.0% | -5.3% | -19.4% | — |
| Nov 18, 2024 | AMC | -1.22 | -1.19 | +2.5% | 19.82 | +5.4% | -13.1% | -11.0% | +1.7% | +30.2% | +10.0% | — |
| Aug 9, 2024 | AMC | -1.02 | -1.09 | -6.9% | 35.59 | -1.3% | -2.5% | -1.5% | -1.8% | +6.1% | -1.7% | — |
| May 10, 2024 | AMC | -1.03 | -1.00 | +2.9% | 32.50 | -1.3% | -5.7% | +3.0% | +6.5% | +0.4% | -1.2% | — |
| Mar 26, 2024 | AMC | -1.17 | -1.51 | -29.1% | 49.45 | -0.1% | -0.4% | +3.3% | -8.1% | -4.7% | -1.5% | — |
| Nov 14, 2023 | AMC | -0.80 | -0.41 | +48.8% | 14.00 | -2.3% | -1.4% | -4.6% | +1.8% | -1.5% | -1.8% | — |
| Aug 10, 2023 | AMC | -0.15 | -0.04 | +73.3% | 12.64 | -0.3% | -1.9% | -0.2% | +8.2% | +4.3% | +3.6% | — |
| Mar 30, 2023 | AMC | -4.40 | -0.26 | +94.2% | 13.90 | -0.7% | +0.7% | +0.0% | -2.9% | +5.9% | -2.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 3 | Rodman & Renshaw | Initiates | Buy | $70 | $26.14 | $26.89 | +2.9% | +0.3% | +4.8% | -3.6% | +8.0% | +0.7% |
| Apr 6 | Canaccord Genuity | Maintains | Buy → Buy | — | $20.69 | $20.69 | +0.0% | -1.1% | +2.1% | +3.3% | -1.1% | -4.6% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.28 | $17.26 | -0.1% | -1.9% | +10.9% | -3.9% | -2.8% | -0.2% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.08 | $30.24 | -2.7% | -14.8% | -14.0% | -1.4% | -4.9% | -1.7% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.14 | $34.46 | +4.0% | +3.4% | -9.3% | +2.4% | -12.8% | -3.8% |
| Oct 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.83 | $26.62 | +3.1% | +22.2% | -4.3% | +4.7% | +5.0% | +3.5% |
| Jun 12 | BMO Capital | Maintains | Outperform → Outperform | — | $20.92 | $21.43 | +2.4% | -2.5% | -3.1% | -4.0% | -2.9% | -0.7% |
| May 20 | BMO Capital | Maintains | Outperform → Outperform | — | $19.52 | $20.39 | +4.5% | -5.0% | -5.7% | +3.1% | -4.2% | -1.1% |
| May 16 | Baird | Downgrade | Outperform → Neutral | — | $19.37 | $18.20 | -6.0% | -7.1% | +8.5% | -5.0% | -5.7% | +3.1% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.70 | $17.21 | -2.8% | -12.4% | -1.9% | +27.3% | -7.1% | +8.5% |
| Apr 14 | BMO Capital | Maintains | Outperform → Outperform | — | $11.00 | $10.97 | -0.3% | -1.0% | +4.3% | -5.2% | +6.7% | +4.6% |
| Mar 25 | Baird | Maintains | Outperform → Outperform | — | $13.96 | $14.17 | +1.5% | +1.7% | +13.7% | -5.0% | -5.3% | -19.4% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.96 | $14.17 | +1.5% | +1.7% | +13.7% | -5.0% | -5.3% | -19.4% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.30 | $21.05 | +3.7% | +10.0% | +20.4% | -4.0% | -1.4% | -3.4% |
| Nov 20 | BMO Capital | Maintains | Outperform → Outperform | — | $17.23 | $17.31 | +0.5% | -11.0% | +1.7% | +30.2% | +10.0% | +20.4% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.82 | $20.90 | +5.4% | -13.1% | -11.0% | +1.7% | +30.2% | +10.0% |
| Nov 12 | Leerink Partners | Maintains | Outperform → Outperform | — | $71.53 | $48.28 | -32.5% | -44.1% | -0.8% | -1.2% | -11.9% | -42.6% |
| Nov 12 | Baird | Maintains | Outperform → Outperform | — | $71.53 | $48.28 | -32.5% | -44.1% | -0.8% | -1.2% | -11.9% | -42.6% |
| Nov 12 | Stifel | Maintains | Buy → Buy | — | $71.53 | $48.28 | -32.5% | -44.1% | -0.8% | -1.2% | -11.9% | -42.6% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $71.53 | $48.28 | -32.5% | -44.1% | -0.8% | -1.2% | -11.9% | -42.6% |
| Nov 12 | BMO Capital | Maintains | Outperform → Outperform | — | $71.53 | $48.28 | -32.5% | -44.1% | -0.8% | -1.2% | -11.9% | -42.6% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.59 | $35.12 | -1.3% | -2.5% | -1.5% | -1.8% | +6.1% | -1.7% |
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.32 | $30.50 | +0.6% | +2.5% | -0.2% | +2.4% | -2.0% | +2.9% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.23 | $37.75 | +1.4% | +1.3% | -0.7% | -0.8% | +1.9% | -1.4% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.50 | $32.09 | -1.3% | -5.7% | +3.0% | +6.5% | +0.4% | -1.2% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.94 | $32.80 | -3.4% | -3.1% | +0.9% | -2.1% | -5.7% | +3.0% |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.39 | $36.02 | +1.8% | +3.5% | -10.4% | +3.4% | -3.1% | +0.9% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.55 | $39.90 | +6.3% | +20.0% | -0.6% | +9.9% | +1.3% | -1.7% |
| Mar 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.55 | $38.55 | +0.0% | -3.4% | +2.0% | +1.8% | -3.7% | -2.1% |
| Jan 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.30 | $33.25 | +2.9% | -6.6% | +0.1% | -0.3% | +0.0% | +0.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Cvijic Christine MikailDir/Off | President and CFO | Sell | 4,200 | $36.13 | $152K | 84,040 | +3.91% | +1.98% |
| Jul 6, 2026 | Cvijic Christine MikailDir/Off | President and CFO | Sell | 600 | $36.02 | $22K | 88,240 | +3.91% | +1.98% |
| Jul 2, 2026 | Cvijic Christine MikailDir/Off | President and CFO | Sell | 1,530 | $35.23 | $54K | 88,840 | -7.87% | -7.49% |
| Jul 2, 2026 | Cvijic Christine MikailDir/Off | President and CFO | Sell | 2,531 | $34.58 | $88K | 90,370 | -7.87% | -7.49% |
| Jul 1, 2026 | Cvijic Christine MikailDir/Off | President and CFO | Sell | 739 | $34.06 | $25K | 92,901 | -7.87% | -7.49% |
| May 6, 2026 | Cvijic Christine MikailDir/Off | President and CFO | Sell | 4,800 | $30.07 | $144K | 98,440 | +0.36% | -4.64% |
8-K
Neurogene Inc. -- 8-K Filing
Jul 2
8-K · 7.01
! Medium
Neurogene Inc. -- 8-K 7.01: Regulation FD Disclosure
Neurogene Inc. will host a conference call today to discuss data results, with details available in the attached press release.
Jun 29
8-K · 7.01
! Medium
Neurogene Inc. -- 8-K 7.01: Regulation FD Disclosure
Neurogene Inc. disclosed updated corporate materials via press release and presentation on June 8, 2026, providing investors with current company information and strategic updates.
Jun 8
8-K · 7.01
! Medium
Neurogene, Inc. -- 8-K 7.01: Regulation FD Disclosure
Neurogene disclosed material information via press release but the 8-K summary doesn't specify the content, so investors should review Exhibit 99.1 directly to assess relevance to NGNE stock.
Apr 20
8-K
Unknown — 8-K Filing
Completion of Embolden trial enrollment and Breakthrough Therapy designation for NGN-401 significantly accelerate NGNE's path to FDA approval, potentially enabling faster commercialization and reducing development risk for this clinical-stage biotech.
Mar 24
8-K · 7.01
! Medium
Neurogene, Inc. -- 8-K 7.01: Regulation FD Disclosure
Neurogene disclosed material information via press release without specifying details, requiring investors to review the attached exhibit to assess potential impacts on the gene therapy company's operations or financial outlook.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Samsara Biocapital, Llc | 1,717,127 | $35M | — | Dec 2025 |
| 2 | Rtw Investments, Lp | 1,362,456 | $27M | — | Mar 2026 |
| 3 | Trails Edge Capital Partners, Lp | 782,787 | $16M | — | Mar 2026 |
| 4 | Morgan Stanley | 742,348 | $15M | Reduced | Dec 2025 |
| 5 | Toronto Dominion Bank | 681,337 | $14M | — | Dec 2025 |
| 6 | Vanguard Capital Management Llc | 514,727 | $10M | New | Mar 2026 |
| 7 | Citadel Advisors Llc | 387,031 | $8M | Added | Mar 2026 |
| 8 | Fmr Llc | 382,647 | $8M | Added | Mar 2026 |
| 9 | Millennium Management | 204,809 | $4M | Added | Mar 2026 |
| 10 | Ubs Group Ag | 185,679 | $4M | Added | Mar 2026 |
| 11 | Blair William & Co/il | 168,218 | $3M | Added | Mar 2026 |
| 12 | Northern Trust Corp | 97,621 | $2M | Added | Mar 2026 |
| 13 | Woodline Partners Lp | 83,835 | $2M | — | Mar 2026 |
| 14 | Vanguard Portfolio Management Llc | 65,080 | $1M | New | Mar 2026 |
| 15 | Jpmorgan Chase & Co | 64,922 | $1M | Added | Mar 2026 |
| 16 | Schroder Investment Management Group | 52,300 | $1M | — | Mar 2026 |
| 17 | Renaissance Technologies Llc | 43,400 | $875K | Added | Mar 2026 |
| 18 | Bank Of New York Mellon Corp | 26,043 | $525K | Added | Mar 2026 |
| 19 | Nuveen, Llc | 25,210 | $508K | Added | Mar 2026 |
| 20 | Jane Street Group, Llc | 15,105 | $311K | Reduced | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$558.0M
Enterprise Value
$491.4M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
5.16x
P/B
2.82x
P/S
—
P/FCF
-9.62x
EV/EBITDA
—
Shares Out
21.2M
Financials (TTM)
Revenue
$0
Net Income
-$98.6M
EBITDA
-$95.5M
Free Cash Flow
-$78.4M
Op Cash Flow
-$77.2M
EPS Basic
$-4.24
EPS Diluted
$-5.03
EPS Forward
$-5.19
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$288.6M
Total Liab.
$23.7M
Total Equity
$264.9M
Cash
$269.0M
LT Debt
$6.8M
Book Value/Sh
$12.51
Debt/Equity
0.04x
Current Ratio
16.56
Quick Ratio
16.56
Returns & Growth
ROE
-34.1%
ROA
-31.3%
ROIC
-37.5%
Rev Growth YoY
-100.0%
EPS Growth YoY
+0.9%
Price Returns
2W
+0.1%
1M
-3.3%
3M
+13.9%
6M
+106.6%
12M
+65.9%
Technicals
52W High
$43.66
52W Low
$15.93
50d MA
$32.30
200d MA
$25.26
RSI (14)
40.40
ATR (14)
$1.84
Beta
1.89
Avg Volume
270K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$69.00
High
$69.00
Low
$69.00
Median
$69.00
Data updated apr 26, 2026 2:57pm
· Source: financialmodelingprep.com